Reynolds Vuse E-Cigarette Market Share Increases, Juul Ranking 2rd

Business by 2FIRSTS.ai
Nov.20.2023
Reynolds Vuse E-Cigarette Market Share Increases, Juul Ranking 2rd
According to Journalnow, Reynolds Tobacco's Vuse e-cigarette market share increases to 42.1%, surpassing Juul's 24.4%.

According to a recent report by Journalnow, Reynolds Tobacco's e-cigarette brand Vuse has seen a slight increase in market share, rising to 42.1%. This surpasses the second-ranked Juul, which has maintained a market share of 24.4%.

 

Meanwhile, the market share of NJoy, a subsidiary of Altria Group and ranked number three, has not significantly increased, remaining at 2.5%.

 

In addition, Altria and British American Tobacco warn that the prevalence of illegal synthetic nicotine e-cigarettes is increasing in the American market. According to estimates by both companies, these illicit synthetic e-cigarette products represent approximately half of the domestic market share in the United States.

 

According to reports, this report covers a four-week period from the previous report until November 4th. Nielsen's data for this report mostly comes from major retail chains.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Scandinavian Tobacco Group Reports Q3 2025 Results and Narrows Full-Year Guidance
Scandinavian Tobacco Group Reports Q3 2025 Results and Narrows Full-Year Guidance
Scandinavian Tobacco Group (STG) reported net sales of DKK 2.4 billion for Q3 2025, in line with last year. EBITDA before special items reached DKK 519 million with a 22.0% margin. Handmade Cigars and Next Generation Products saw organic growth, while Machine-Rolled Cigars and Smoking Tobacco declined. The company narrowed its full-year guidance.
Nov.12 by 2FIRSTS.ai
Product | Pouchless Oral Nicotine NAKD Nicotine Pods Launch with “Garlic-Clove” Shape and Structural Design Drawing Attention
Product | Pouchless Oral Nicotine NAKD Nicotine Pods Launch with “Garlic-Clove” Shape and Structural Design Drawing Attention
NAKD nicotine pods have been launched overseas with a pouchless solid-pellet design, featuring a “garlic clove–like” appearance that is smaller than traditional nicotine pouches. Made from compostable materials and positioned around instant nicotine release, the product is developed by Norwegian brand Den Norske Snusfabrikken and is already available in several European markets.
Nov.18 by 2FIRSTS.ai
Philip Morris Korea Launches New TEREA Packaging for IQOS ILUMA to Mark Third Anniversary
Philip Morris Korea Launches New TEREA Packaging for IQOS ILUMA to Mark Third Anniversary
Philip Morris Korea has announced a new packaging design for TEREA, the dedicated tobacco stick brand for its heat-not-burn device IQOS ILUMA, to celebrate the third anniversary of its launch in South Korea. The newly designed products are now available at nine IQOS flagship stores and major convenience stores across the country.
Nov.13 by 2FIRSTS.ai
KT&G Nears ASF Acquisition, Preparing Wide Regional Nicotine Pouch Expansion
KT&G Nears ASF Acquisition, Preparing Wide Regional Nicotine Pouch Expansion
South Korean outlet nate reports that KT&G expects to finalize its acquisition of Nordic nicotine pouch maker ASF within this year. Beginning next year, the company plans to expand the business well beyond ASF’s current five Nordic markets to Europe, the Middle East, Africa, Asia and North America, supported by its cooperation framework with Altria.
Nov.25
Polish Government Plans Ban on Flavoured Nicotine Pouches and Disposable E-Cigarettes
Polish Government Plans Ban on Flavoured Nicotine Pouches and Disposable E-Cigarettes
Poland’s government is preparing to amend the Act on Protection of Health from the Consequences of Tobacco Use to ban the sale of flavoured nicotine pouches and disposable e-cigarettes. The Health Ministry says the goal is to protect youth from nicotine addiction, citing World Health Organization data on the risks of such products. However, industry representatives and legal experts argue the proposal is abrupt and could expand the illicit market.
Dec.05 by 2FIRSTS.ai
ceshi1111
ceshi1111
Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st
Oct.21